Skip to main content

Table 1 Patient Characteristics

From: Parotid gland sparing IMRT for head and neck cancer improves xerostomia related quality of life

 

IMRT % (n = 75)

Control % (n = 87)

Male (n)

72

64

Female (n)

28

36

Mean dose primary tumour

69 Gy

70 Gy

Mean age start RT

59 yrs

59 yrs

Mean interval between RT and Questionnaire

2.3 yrs

2.9 yrs

Tumour Site

  

   Hypopharynx

9

9

   Larynx

31

31

   Nasopharynx

7

6

   Oral cavity

7

8

   Oropharynx

37

45

   Thyroid

7

0

   Other

3

1

T-stage

  

   T1

16

5

   T2

37

27

   T3

25

33

   T4

22

35

N-stage

  

   N0

50

39

   N1

15

13

   N2

36

48

Larynx

  

   T1-2 (n)

18

15

   T3-4 (n)

5

12

Oropharynx

  

   T1-2 (n)

10

5

   T3-4 (n)

14

27

Concommittant chemotherapy

39

53

Surgery

24

15

Gastrostomy

3

6

Xerostomia related medication

17

20